The S&P/ASX 200 Index (ASX: XJO) is having a reasonably poor start to the week. In afternoon trade, the benchmark index is down 0.45% to 8,921.3 points.
Four ASX shares that are not letting that hold them back today are listed below. Here’s why they are rising:
Monash IVF Group Ltd (ASX: MVF)
The Monash IVF share price is up 14% to 75.7 cents. This morning, the fertility treatment company revealed that it has received a new non-binding takeover proposal from a consortium that includes Washington H. Soul Pattinson and Co Ltd (ASX: SOL). The consortium had previously offered 80 cents per share. This has now been increased to 90 cents per share and “represents the highest amount the Consortium is prepared to offer as its Offer Price, absent a competing proposal emerging for all or a material part of Monash IVF.” The company advised that its board is assessing the proposal, including obtaining advice from its financial and legal advisers.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is up 5% to $133.14. This morning, the health imaging technology company announced that it has signed a five-year contract renewal with Northwestern Medicine. Importantly, the $37 million contract has increased minimums and an increased fee per transaction. Commenting on the deal, Pro Medicus’ CEO, Dr Hupert, said: “We are extremely pleased that in addition to committing to a second five-year term at an increased fee per exam, NM have also committed to an increase in their minimums reflecting the growth in their exam volumes since standardising on our platform five years ago.”
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix Pharmaceuticals share price is up 8% to $15.87. Investors have been buying the radiopharmaceuticals company’s shares after it announced a major collaboration with US-based Regeneron Pharmaceuticals (NASDAQ: REGN). The company notes that there is potential to earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties if Telix opts out of co-funding any program. Telix’s managing director and CEO, Christian Behrenbruch, said: “The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients.”
Woodside Energy Group Ltd (ASX: WDS)
The Woodside Energy share price is up almost 3% to $34.19. This energy giant’s shares are rising today after oil prices jumped above US$100 a barrel. The catalyst for the jump was news that US President Donald Trump is threatening to blockade Iranian ports after initial peace talks between the two countries failed.
The post Why Monash IVF, Pro Medicus, Telix, and Woodside shares are storming higher today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Monash IVF Group right now?
Before you buy Monash IVF Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Monash IVF Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- How ASX 200 energy stocks like Woodside and Santos are surging in Monday’s sinking market
- Buy, hold, sell: AGL, Origin Energy, and Woodside shares
- Telix share price leaping higher today on $3 billion US news
- These are the 10 most shorted ASX shares
- Why are Pro Medicus shares outperforming the market on Monday?
Motley Fool contributor James Mickleboro has positions in Pro Medicus and Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Regeneron Pharmaceuticals, Telix Pharmaceuticals, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Pro Medicus and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.